Cure My Disease

Don't miss your cure!

 Log in / Sign up

Race against time: new drug aims to slow devastating ALS

NCT ID NCT06643481

Ongoing Disease control Sponsor: Novartis Pharmaceuticals Source: ClinicalTrials.gov ↗

Summary

This study is testing whether an experimental drug called VHB937 can slow the progression of early-stage ALS (Lou Gehrig's disease). It will involve 251 adults who have had ALS symptoms for less than two years. Participants will receive either the drug or a placebo for 40 weeks, followed by an optional period where everyone can receive the drug, to see if it helps people live longer without permanent breathing assistance and maintain daily function.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for AMYOTROPHIC LATERAL SCLEROSIS (ALS) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • AMR Knoxville

    Knoxville, Tennessee, 37920, United States

  • Atrium Health

    Charlotte, North Carolina, 28207, United States

  • Austin Neuromuscular Center

    Austin, Texas, 78759, United States

  • Duke University Health System

    Durham, North Carolina, 27710, United States

  • Emory University School of Medicine

    Atlanta, Georgia, 30322, United States

  • Johns Hopkins University School of Medicine

    Baltimore, Maryland, 21287, United States

  • Keck Medical Center USC

    Los Angeles, California, 90033, United States

  • Lange Neurology PC

    New York, New York, 10065, United States

  • Loma Linda University Health

    Loma Linda, California, 92354, United States

  • Massachusetts General Hospital

    Boston, Massachusetts, 02114, United States

  • Nerve and Muscle Center of Texas

    Houston, Texas, 77030, United States

  • Neurology Associates P C

    Lincoln, Nebraska, 68506-2960, United States

  • Novartis Investigative Site

    North Ryde, New South Wales, 2109, Australia

  • Novartis Investigative Site

    Randwick, New South Wales, 2031, Australia

  • Novartis Investigative Site

    Herston, Queensland, 4029, Australia

  • Novartis Investigative Site

    Cauldfield, Victoria, 3162, Australia

  • Novartis Investigative Site

    Southport, 4215, Australia

  • Novartis Investigative Site

    Leuven, 3000, Belgium

  • Novartis Investigative Site

    Liège, 4000, Belgium

  • Novartis Investigative Site

    Calgary, Alberta, T2N 4N1, Canada

  • Novartis Investigative Site

    Hamilton, Ontario, L8N 3Z5, Canada

  • Novartis Investigative Site

    Montreal, Quebec, H2X 0A9, Canada

  • Novartis Investigative Site

    Montreal, Quebec, H4A 3T2, Canada

  • Novartis Investigative Site

    Beijing, 100191, China

  • Novartis Investigative Site

    Aalborg, 9000, Denmark

  • Novartis Investigative Site

    Kobenhavn N V, 2400, Denmark

  • Novartis Investigative Site

    Turku, 20521, Finland

  • Novartis Investigative Site

    Limoges, Haute Vienne, 87000, France

  • Novartis Investigative Site

    Bron, 69677, France

  • Novartis Investigative Site

    Lille, 59037, France

  • Novartis Investigative Site

    Montpellier, 34090, France

  • Novartis Investigative Site

    Nice, 06001, France

  • Novartis Investigative Site

    Paris, 75013, France

  • Novartis Investigative Site

    Tours, 37044, France

  • Novartis Investigative Site

    Mannheim, Baden-Wurttemberg, 68167, Germany

  • Novartis Investigative Site

    Munich, Bavaria, 81675, Germany

  • Novartis Investigative Site

    Würzburg, Bavaria, 97080, Germany

  • Novartis Investigative Site

    Rostock, Mecklenburg-Vorpommern, 18057, Germany

  • Novartis Investigative Site

    Berlin, 13353, Germany

  • Novartis Investigative Site

    Hanover, 30559, Germany

  • Novartis Investigative Site

    Lübeck, 23538, Germany

  • Novartis Investigative Site

    Münster, 48149, Germany

  • Novartis Investigative Site

    Ulm, 89081, Germany

  • Novartis Investigative Site

    Dublin, DUBLIN 9, Ireland

  • Novartis Investigative Site

    Milan, MI, 20138, Italy

  • Novartis Investigative Site

    Modena, MO, 41126, Italy

  • Novartis Investigative Site

    Pisa, PI, 56126, Italy

  • Novartis Investigative Site

    Torino, TO, 10126, Italy

  • Novartis Investigative Site

    Nagoya, Aichi-ken, 466 8560, Japan

  • Novartis Investigative Site

    Sendai, Miyagi, 980 8574, Japan

  • Novartis Investigative Site

    Ohtsu, Shiga, 520-2192, Japan

  • Novartis Investigative Site

    Tokushima, Tokushima, 770-8503, Japan

  • Novartis Investigative Site

    Ōta-ku, Tokyo, 143 8541, Japan

  • Novartis Investigative Site

    Utrecht, 3584 CX, Netherlands

  • Novartis Investigative Site

    Krakow, Poland, 31 531, Poland

  • Novartis Investigative Site

    Bydgoszcz, 85-163, Poland

  • Novartis Investigative Site

    Krakow, 30-721, Poland

  • Novartis Investigative Site

    Warsaw, 01-684, Poland

  • Novartis Investigative Site

    Warsaw, 02-473, Poland

  • Novartis Investigative Site

    Yangsan, Gyeongsangnam-do, 50612, South Korea

  • Novartis Investigative Site

    Seoul, 04763, South Korea

  • Novartis Investigative Site

    Seoul, 05505, South Korea

  • Novartis Investigative Site

    L'Hospitalet de Llobregat, Barcelona, 08907, Spain

  • Novartis Investigative Site

    Donostia / San Sebastian, Basque Country, 20080, Spain

  • Novartis Investigative Site

    Barcelona, Catalonia, 08003, Spain

  • Novartis Investigative Site

    Barcelona, Catalonia, 08035, Spain

  • Novartis Investigative Site

    Santiago, Corunja, 15706, Spain

  • Novartis Investigative Site

    Madrid, 28029, Spain

  • Novartis Investigative Site

    Málaga, 29010, Spain

  • Novartis Investigative Site

    Valencia, 46026, Spain

  • Novartis Investigative Site

    Malmo, 214 28, Sweden

  • Novartis Investigative Site

    Stockholm, 113 61, Sweden

  • Novartis Investigative Site

    Umeå, SE-90185, Sweden

  • Novartis Investigative Site

    Basel, 4031, Switzerland

  • Novartis Investigative Site

    Sankt Gallen, 9007, Switzerland

  • Novartis Investigative Site

    Sheffield, South Yorkshire, S10 2JF, United Kingdom

  • Novartis Investigative Site

    Farnborough, BR6 8ND, United Kingdom

  • Novartis Investigative Site

    London, SW17 0QT, United Kingdom

  • Novartis Investigative Site

    London, WC1N 3BG, United Kingdom

  • Novartis Investigative Site

    Stoke-on-Trent, ST4 6QG, United Kingdom

  • Orlando Health Clinical Trials

    Orlando, Florida, 32806, United States

  • Providence ALS Center

    Portland, Oregon, 97213, United States

  • Temple University

    Philadelphia, Pennsylvania, 19140, United States

  • The Ohio State University

    Columbus, Ohio, 43210, United States

  • UC San Francisco Medical Center

    San Francisco, California, 94143, United States

  • Univ of Cincinnati Medical Center

    Cincinnati, Ohio, 45219, United States

  • University Of Kansas Medical Center

    Kansas City, Kansas, 66160, United States

  • University of California San Diego

    La Jolla, California, 92037, United States

  • University of Miami

    Miami, Florida, 33136, United States

  • University of Nebraska Medical Center

    Omaha, Nebraska, 68198, United States

  • University of Rochester Medical Center

    Rochester, New York, 14642, United States

  • University of Washington Medical Center

    Seattle, Washington, 98195, United States

Conditions

Explore the condition pages connected to this study.

AMYOTROPHIC LATERAL SCLEROSIS (ALS)